Found 694 clinical trials
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.
- 0 views
- 19 Feb, 2024
- 3 locations
Driving Pressure in Neurosurgery
Center of ventilation (COV) by EIT, as well as the lung ultrasonographyLUS), perioperative ventilatory parameters, arterial oxygenation index (PaO2/FiO2) , serum indicators and postoperative pulmonary complications are secondary outcome variables.
- 0 views
- 19 Feb, 2024
- 1 location
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers.
- 0 views
- 19 Feb, 2024
- 39 locations
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation. The hypothesis is that clinical differences in course of disease reflect underlying …
- 0 views
- 19 Feb, 2024
- 2 locations
Dupilumab Asthma Sleep Study
Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: To evaluate the effect of dupilumab on additional patient reported sleep outcomes To evaluate the effect of dupilumab on objective sleep assessment To evaluate the effect of dupilumab on asthma symptoms To evaluate the effect of dupilumab on …
- 0 views
- 24 Nov, 2025
- 11 locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC
This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …
- 0 views
- 19 Feb, 2024
- 28 locations
Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment
This is a Phase 1, two-part, two-arm, open-label study in patients with NSCLC who have had 1 or 2 prior lines of treatment, with 1 line containing a CPI, or patients with CRC who have had 2 prior lines of treatment (oxaliplatin- and irinotecan-based) and no prior immunotherapy. The study …
- 0 views
- 19 Feb, 2024
- 3 locations
Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction
Clinical evaluation of a new educative tools (Smartphone application) based on impact of instrumental dead space reduction after initiation of protective ventilation during mechanical ventilation.
- 0 views
- 19 Feb, 2024
- 1 location
Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
Whether isolated SSPE represents "true" PE, a clinically more benign form of PE, a physiologic lung clearing process, or a false positive result (artifact) is currently unclear and hence, whether patients with isolated SSPE benefit from anticoagulant treatment is uncertain.
- 0 views
- 19 Feb, 2024
- 31 locations
Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
Participants are assigned to one of 8 cohorts based on their primary tumour type: breast, lung, gastrointestinal (GI), primary unknown, genitourinary (GU), sarcoma, gynecological, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks).
- 0 views
- 19 Feb, 2024
- 1 location